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Abstract: Artificial liver support aims to prolong survival
time of patients with liver failure by detoxification. Albu-
min as a molecular adsorbent in dialysis solution is capable
of attracting even tightly albumin-bound toxins from blood
into the dialysate if a specific dialysis membrane is used
and if the albumin’s binding sites are on-line-purified by a
sorbent/dialysis-based recycling system (i.e., molecular ad-
sorbents recycling system, or MARS). The MARS tech-
nology has been shown to remove water-soluble and albu-
min-bound toxins and to provide renal support in case of
renal failure. Fourteen centers have reported that MARS
treatment improved mental status of patients with liver
failure and hepatic encephalopathy. In treating liver fail-
ure and cholestasis, MARS was associated with hemody-
namic stabilization, improvement of hepatic and kidney
function, and disappearance of pruritus. In hepatic failure
and hepatorenal syndrome, a prospective, randomized,
controlled trial of MARS treatment was able to prolong
survival time significantly. MARS has been used in 26 pa-
tients with acute liver failure or primary graft dysfunction.
Nineteen centers reporting on 103 patients have shown
that MARS treatment is safe, easy to handle, feasible, and
effective. Key Words: Albumin dialysis—Clinical tri-
als—Liver failure—Liver support—Molecular adsorbents
recycling system—Multicenter trials.
Hepatic failure is a clinical syndrome that results
from loss of functional liver cell mass below a critical
level. This may be due to toxic-, viral-, or ischemic-
induced massive hepatocyte necrosis in a formerly
healthy liver causing acute liver failure, or it may be
due to a precipitating event that complicates chronic
liver disease in a patient with already limited func-
tional hepatic capacity. The latter is acute decom-
pensation of chronic liver disease and is called acute
on chronic liver failure. As a result, the major liver
functions, particularly detoxification, synthetic func-
tions, and metabolic regulation will be impaired to
different degrees, and as such, perpetuate each
other. The imbalance between the physiological
needs and the functions provided by the injured liver
results in major life-threatening complications of
liver insufficiency such as hepatic encephalopathy
and coma, jaundice and cholestasis, ascites, renal
failure, bleeding, immune disorders, and sepsis.
The current standard medical therapy (SMT) in-
volves measures to treat complications and prevent
further deterioration until the precipitating event
can be managed in case of acute on chronic liver
failure or the liver spontaneously recovers as a pos-
sible outcome in acute liver failure. Failure of these
attempts leaves liver transplantation as the only vi-
able treatment option. However, orthotropic liver
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transplant is not readily available for most patients
due to the shortage in cadaveric organs.
The management of the precipitating event of
liver failure until enough liver cells can help regain
its function, regenerate, or an organ becomes avail-
able for transplant, requires time. Hence, time re-
mains the crucial factor in successfully managing
liver failure. Liver support technology is evolving as
different techniques to assist the remaining func-
tional cell mass by providing specific liver functions
become available. The major objective of liver sup-
port is buying time.
Earlier attempts to provide liver support included
the use of several extracorporeal detoxification pro-
cedures such as hemofiltration or hemodialysis,
plasma exchange, and hemoperfusion or plasma per-
fusion using charcoal- or polymer-based sorbents.
These procedures proved to be safe, particularly
hemofiltration, which had beneficial effects in some
patients with hepatic encephalopathy. However,
they were not significantly effective in removing al-
bumin-bound toxic molecules due to their high bind-
ing affinity to albumin and to their inability to per-
meate dialysis membranes (1).
Plasma exchange was associated with major side
effects that prevented the extended use that would
be necessary for effective detoxification (2).
The use of nonspecific sorbents such as charcoal
or ion exchangers in direct contact with blood or
plasma resulted in effective removal of toxic mol-
ecules, but was also complicated by bioincompatibil-
ity, which resulted in alarming drops in fibrinogen,
and by activation of complements, which resulted in
systemic inflammatory response (2–4). In addition,
the direct contact between sorbents and plasma pro-
teins has been shown to result in removal of hepa-
tocyte growth factor (5) and a number of hormones
such as growth hormone (3), triiodothyronine (T3),
tetraiodothyronine (T4), (3,6–8), parathormone (9),
testosterone, steroid hormones, and insulin (3,10,11).
Attempts to reduce these unwanted effects of di-
rect contact between sorbents and plasma proteins
involved the use of membranes that separate blood
and the unspecific sorbent. One membrane used is a
cellulose flat membrane that has a similar permeabil-
ity to that of a standard low-flux cellulose dialyzer
(12). Although it improved hepatic encephalopathy
in some patients, it does not allow removal of the
albumin-bound fraction of toxic molecules. In fact,
bilirubin, which is a marker for albumin-bound tox-
ins, increased during the treatment using this mem-
brane (13).
Another membrane used had a pore size large
enough to allow albumin as the toxin carrier to pass
through, but had a lower sieving coefficient for large
plasma proteins such as immunoglobulin M (IgM)
(14). Furthermore, as many valuable molecules have
a molecular weight close to albumin, there is a loss of
valuable substances such as immunoglobulin G
(sieving coefficient >70%), high-density lipoprotein
(sieving coefficient 65%), and fibrinogen (sieving co-
efficient 17%) (14). Studies regarding the loss of
other molecules that have similar molecular size to
albumin, such as antithrombin III, transthyretin,
transcortin, and so forth, and which also have high
sieving coefficients, have not yet been published. Us-
ing this type of fractionated plasma separation in
vivo resulted in a drop of serum bilirubin and an
improvement of hepatic encephalopathy (13).
Thus, plasmasorption using albumin-permeable
membranes to filtrate plasma or plasma fractions in
order to perfuse it over unspecific sorbents to re-
move protein-bound toxins was not efficient in the
management of liver failure in prospective, con-
trolled randomized studies.
Recent developments have focused on the use of
liver cells in extracorporeal systems to improve and
substitute some of the liver functions during acute
liver failure. As adult human hepatocytes cannot be
produced in culture in adequate amounts, different
systems use porcine hepatocytes (15) or human hep-
atoma cells (16). Two of these systems are currently
being tested for their efficacy on patients with acute
liver failure.
The goal of removing albumin-bound toxic mol-
ecules that accumulate in liver failure in an effective
but also selective biocompatible manner has not
been achieved with current conventional methods.
THE METHOD OF ALBUMIN DIALYSIS
Albumin dialysis is a new method that combines
the efficacy of sorbents to remove albumin-bound
molecules with the biocompatibility of the modern
dialysis membrane. It is selective in removing pro-
tein-bound molecules that use albumin as a specific
toxin carrier in human blood. Thus, albumin dialysis
is an extracorporeal liver support system based on
the concept of dialysis, using a specific membrane
(Teraklin AG, Rostock, Germany, cut-off 50,000,
sieving coefficient for albumin less than 0.01) and
albumin as the dialysate. The albumin acts as a spe-
cific molecular adsorbent that is regenerated on-line
by recirculating in a recycling system (i.e., molecular
adsorbents recycling system, or MARS, trademark
of Teraklin AG, Rostock, Germany). Due to the
attracting effect of albumin, the system achieves high
clearance of albumin-bound substances such as bile
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acids and bilirubin, which are not removed by hemo-
filtration. The membrane used in MARS is capable
of releasing the albumin-ligand complex present in
the blood due to its physicochemical ability to inter-
act with lipophilic binding domains. The membrane
itself is impermeable to albumin and other valuable
proteins such as hormones, clotting factors, and an-
tithrombin III and is highly tolerated in clinical use.
The two sorbent columns and the dialyzer allow the
removal of both protein-bound and water-soluble
toxins, thus making the system useful for patients
with liver failure complicated by renal insufficiency.
Furthermore, additional organ support is provided
by maintaining electrolyte, acid/base, fluid balance,
glucose level, and by removing ammonia, a water-
soluble toxin that accumulates in liver failure.
In summary, the membrane is biocompatible,
which ensures a safe long-term use with no or mini-
mal need of anticoagulation and with minimal effect





In laboratory investigations, it has been shown by
several groups that even tightly albumin-bound
molecules such as unconjugated bilirubin can be re-
moved by dialysis using specific albumin-
impermeable dialysis membranes and an albumin-
containing dialysate solution (17–20). In vitro
investigations using fluorescence-labeled albumin
have shown that toxins travel across the membrane,
reaching the dialysate solution where they are bound
by albumin (21). The driving force for the mass
transport of albumin-bound molecules from the
blood through the membrane is the greater availabil-
ity of free binding sites of the highly purified albu-
min in the dialysate compartment (22).
Known protein-bound substances cleared by the
MARS system
In 8 consecutive patients receiving 1 single treat-
ment of MARS, the mean reduction of serum bili-
rubin as a marker for albumin-bound molecules was
35% compared to baseline (23). This was superior to
the reduction rates (24%) reported by albumin-
permeable membranes in fractionated plasmapher-
esis in vivo (13).
Furthermore, dialysis using this type of membrane
and albumin in the dialysate solution increased the
removal of a number of substances having a high
albumin affinity including bile acids (24), benzodiaz-
epines (25), copper (26), middle-chain fatty acids
(27), arachidonic acid (28), tryptophane (21), IL-6
(29), and TNF-a (29). In addition, reduction of aro-
matic amino acids associated with an increase of
branched-chain amino acids was observed in patients
with liver failure who were treated with MARS (21).
Known water-soluble substances cleared by the
MARS system
MARS involves an actual dialysis circuit contain-
ing albumin which allows the system to function as
hemofiltration. This property is effective in clearing
serum ammonia (24,30), creatinine (24), and urea
(24) at certain flow rates.
Impact on valuable molecules
The plasma levels of proteins with a molecular
weight close to albumin, such as antithrombin III,
transferrin, thyroglobulin, and al-antitrypsin, did not
change during the treatment (21,24). Other physi-
ologically valuable substances bound to transport
proteins other than albumin, such as T3 and T4,
which are bound to thyroxin-binding globulin, also
were unchanged (21).
Laboratory animal evaluation
Awad and colleagues (31) evaluated the MARS
concept in an animal model of cholestatic liver fail-
ure. Dogs were studied 1 week after portocaval
shunt and bile duct ligation which caused parenchy-
mal injury and excretory failure (32). A 6 h treat-
ment with MARS hemodiafiltration decreased bili-
rubin, ammonia, and aromatic amino acids.
RESULTS FROM CLINICAL TRIALS
Results in chronic liver disease complicated by
hepatorenal syndrome
Two centers participated in the first prospective,
randomized controlled trial to investigate the influ-
ence of albumin dialysis using MARS in patients suf-
fering from end-stage liver disease and hepatorenal
syndrome Type-I (33). A summary of baseline pa-
rameters and results is given in Table 1. All patients
were Child Turquotte Class C and had elevated se-
rum bilirubin (mean serum bilirubin >20 mg/dl). All
13 patients were oliguric or anuric and had a urine
sodium <20 mmol/L, despite having adequate intra-
vascular volume (CVP 10 mm Hg). Patients were
randomized to standard medical therapy including
hemodiafiltration or MARS treatment. MARS treat-
ment was well tolerated and resulted in a significant
removal of bilirubin as a marker for albumin-bound
molecules. Furthermore, kidney function and creat-
inine levels also improved significantly in the MARS
group compared to the control group. Associated
with all these physiological improvements, a prolon-
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gation in survival time was achieved in the MARS
group and was statistically significant (Table 1). The
hemodynamic effects of the MARS treatment in
end-stage liver disease were investigated in another
trial (23). Eight patients suffering from acute decom-
pensation of chronic liver disease received a single
MARS treatment. All patients were Child Turcotte
Class C and had a serum bilirubin higher than 15
mg/dl. Five patients had hepatorenal syndrome as
well. After the treatment, the mean bilirubin was
reduced to 65.4% and creatinine to 48.4% compared
to baseline. There was a statistically significant im-
provement in the mean arterial pressure resulting
from an increase of systemic vascular resistance (23).
The hemodynamic improvement was associated with
the reduction in plasma renin activity (23).
Results in chronic liver disease complicated
by cholestasis
Because MARS has the ability to clear bilirubin
and bile acids, it was used in patients with end-stage
liver disease (ESLD) and cholestasis (34). Twenty-
six consecutive patients with ESLD and cholestasis
were included in the study after an initial trial of
SMT without improvement. Their serum bilirubin
was higher than 15 mg/dl, and 23 patients had he-
patic encephalopathy, 11 had refractory ascites, 14
had hepatorenal syndrome, and 23 had detectable
infections. Patients received treatments every day or
every other day depending on a patient’s condition.
The mean number of treatments was 5.5 per patient.
A 6 h MARS treatment resulted in significant reduc-
tion of serum bile acid and serum bilirubin levels.
There was significant improvement in hepatic en-
cephalopathy, and all patients on MARS had an im-
provement in their Child Turquotte Pugh score.
Similar findings were reported by another group
that studied patients with ESLD and acute decom-
pensation presenting with hepatic encephalopathy
(35). The group reported reduction of serum biliru-
bin and ammonia levels and a considerable neuro-
logical improvement in all patients. Using central ve-
nous monitoring, they also confirmed an increase in
systemic vascular resistance associated with an in-
crease of mean arterial pressure.
Results in acute liver failure
A phase-I pilot study using MARS in acute liver
failure as a bridge to liver transplant is actively re-
cruiting patients (36). Preliminary data show that the
procedure is well tolerated, the serum ammonia level
decreased significantly, hepatic coma score im-
proved, and the ratio between branched-chain and
aromatic amino acids increased significantly. In ad-
dition, there was a significant increase in clotting fac-
tor VII as a marker for hepatocyte synthetic func-
tion. Of the 5 patients enrolled in this study who
were United Network Organ Sharing (UNOS) status
1, 1 patient recovered his native hepatic function,
and 3 patients were successfully bridged to trans-
plantation. It is worth mentioning that one of the
patients who was retransplanted was anhepatic and
on MARS therapy for 70 h.
In another center using MARS in fulminant hepa-
titic failure, 4 patients were bridged until a transplant
became available (37). This center’s experience con-
firmed significant reduction of serum ammonia and
bilirubin and neurological improvement.
Two cases with fulminant Wilson disease (26,38)
TABLE 1. A summary of clinical baseline and results of a prospective, randomized, controlled two-center trial in liver
failure complicated by hepatorenal syndrome (31)
Control group MARS group
Baseline
Mean urine output <500 ml/day; NS
Mean CVP >10 mm H2O; NS
Mean CTP >12; NS
Mean serum bilirubin >20 mg/dl; NS
Mean PT value (Quick) <40%; NS
Mean age <50 years old; NS
Gender 4/6 female/male; NS
Results
MAP
Before MAP <70 mm Hg, NS
After <60 mm Hg p < 0.05 >80 mm Hg
Creatinine
Before >3 mg/dl, NS
After >3 mg/dl p < 0.05 <3 mg/dl
PT value after treatment Not significantly changed Significantly increased
Bilirubin after treatment Not significantly changed Significantly reduced
Survival time analyis <7 days Significant prolongation in survival time (p < 0.05)
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complicated by renal failure, toxic hemolysis, and
hepatic encephalopathy were treated with albumin
dialysis. Both patients recovered at 3 and 8 weeks,
respectively, and were transplanted. The copper re-
moval rate obtained by MARS exceeded the re-
moval rate obtained by plasma exchange, and the
renal excretion of penicillamine was used as chelator
(23).
Another center reported the use of MARS in a
49-year-old patient suffering from fulminant liver
failure due to acetaminophen toxicity (39). The pa-
tient had hepatic coma, increased intracranial pres-
sure, and severe coagulopathy (INR 4.1). She was
listed for liver transplantation status 1. Her course
was complicated by kidney failure, acidosis, and se-
vere hypoglycemia. MARS treatment was initiated
to keep the patient alive until a liver for transplant
became available. Reduction of intracranial pressure
and improvement of neurological function and he-
modynamic status was observed within the first 24 h
after the start of treatment. After 3 days on MARS,
the patient’s liver function improved, and MARS
was stopped. The patient recovered without need of
transplantation (39).
Results in primary graft dysfunction
MARS therapy has been used in the treatment of
primary graft dysfunction complicating split liver
transplantation. In one center out of 4 grafts with
primary graft dysfunction and cholestasis, 3 recov-
ered, and 1 patient was retransplanted successfully
(40). At another center, an infant patient with pri-
mary graft dysfunction complicating a split liver
transplantation was treated with MARS (41). The
patient’s condition was stabilized until retransplan-
tation 2 weeks later. Six other patients with primary
graft dysfunction and bilirubin greater than 15 mg/dl
were treated with MARS (37). Five grafts recovered,
eliminating the need for retransplantation. In case
reports from two other centers, 2 out of 3 patients
were bridged to retransplantation (42,43).
Results in other applications
As a result of the effectiveness of MARS in re-
moving molecules that accumulate in cholestasis, it
has been used to treat a patient suffering from be-
nign recurrent intrahepatic cholestasis. A 36-year-
old man suffering for 20 years from attacks of cho-
lestasis lasting 5–6 weeks and associated with
intolerable pruritus received 3 single treatments. The
pruritus improved clinically faster than in any of the
patient’s earlier attacks (44). The capability of
MARS to increase systemic vascular resistance and
mean arterial pressure suggested its use in patients
awaiting heart transplantation whose liver failure is
complicating ventricular heart failure (45). The
treatment resulted in improvement in hepatic en-
cephalopathy and a drop in bilirubin. Whether the
treatment can significantly improve the clinical out-
come in this group of patients is under investigation
in a randomized controlled trial.
DISCUSSION
The current literature contains evidence that
MARS is effective in the treatment of chronic liver
disease complicated by hepatorenal syndrome and
cholestasis. MARS treatment results in improve-
ment in systemic hemodynamic status, renal func-
tion, and hepatic encephalopathy. These changes
brought about improvement of the Child Turqotte
Pugh score of patients.
The different mechanisms responsible for these
improvements are not completely clear. However,
the improvement in the outcomes of patients treated
with MARS could not only be attributed to removal
of bilirubin alone because bilirubin is but an indirect
marker for albumin-bound molecules that accumu-
late in patients with liver failure and is nontoxic. A
number of investigators indicate that toxic bile acids
are involved in the pathophysiological changes seen
in cholestasis and may be even toxic to the liver (46).
The reduction of serum bile acid levels by MARS
treatment was associated with a reduced toxicity of
the plasma of patients if applied to primary hepato-
cytes in culture (34). Other molecules bound to al-
bumin that may be involved in the clinical effects
seen during MARS treatments are endogenous va-
sodilators such as nitric oxide (47), which has been
shown to accumulate in patients with liver failure
(48). Whether an endogenous vasodilator is removed
by albumin dialysis or albumin dialysis removes mol-
ecules that compete with an endogenous vasodilator
for binding sites has yet to be examined. The extra-
corporeal removal of albumin-bound molecules by
MARS reduces competitors for serum albumin bind-
ing sites, and provides more available binding sites in
the microcirculation for binding free toxic molecules.
CONCLUSIONS
Increasing survival time is the major goal of liver
support. The ability of the current MARS technique
to prolong significantly survival time in patients with
hepatorenal syndrome complicating severe cholesta-
sis has been shown in a prospective, controlled ran-
domized trial. The use of long-term albumin dialysis
to support patients awaiting elective liver transplan-
tation in case of decompensation was reported by
Seige and colleagues (49). The efficacy and cost ef-
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ficiency of albumin dialysis can be improved by using
sorbent-based recycling as done by the MARS tech-
nique (50). To date, more than 500 MARS treat-
ments have been done in more than 200 patients.
One hundred and three of these patients are re-
ported in the literature. An overview of reported
data is given in Table 2. Data from 19 centers re-
porting on 103 patients show that albumin dialysis
using MARS is safe, easy to handle, and feasible. It
has been shown to be effective in liver failure com-
plicated by hepatic encephalopathy or cholestasis
and has been associated with clinical improvement.
A prospective, controlled randomized two-center
trial has shown that MARS is able to prolong sur-
vival time significantly.
Ongoing prospective, randomized, controlled tri-
als elucidating the efficacy and cost-effectiveness of
MARS versus standard medical treatment in man-
aging decompensated chronic liver disease are un-
derway to determine whether MARS can shorten
TABLE 2. A summary of multicenter clinical experiences
Reference center
Reported indications (n)
ResultsAoC A PGD Other Total
Awad et al. (36), Michigan 4 5 9 Neurological improvement, bridge to liver
transplant (LTx), reduction of ammonia,
increase of Fischer index and factor VII
Schmidt et al. (23,30), Copenhagen 8 8 Increase of SVR, MAP, and cerebral perfusion,
neurological improvement, decrease of serum
renin activity, bilirubin, ammonia, creatinine
Sorkin et al. (35), Tel Aviv 8 8 Neurological improvement, reduction of
intracranial pressure (ICP), reduction of SjvO2,
reduction of serum bilirubin, ammonia
Novelli et al. (37), Rome 4 6 10 Neurological improvement, bridge to LTx,
reduction of serum ammonia, bilirubin, and
INR
Stange et al. (34), Rostock 26 26 Neurological improvement, reduction of ascites,
bilirubin, PT, bile acids, creatinine, and CTP
Jost et al. (42), Leipzig 7 1 3a 11 Bridge to LTx, decrease of PT, increase of choline
esterases
Delafosse et al. (43), Lyon 1 2 2b 5 Neurological improvement in chronic patient
Siewert-Delle et al. (39), Göteborg 1 1 Neurological and hemodynamic improvement,
reduction of ICP and INR, spontaneous
recovery
Manz et al. (38), Freiburg 1 1 Bridge to elective LTx, reduction of serum copper
and bilirubin in acute WD
Kreymann et al. (26), Munich 1 1 Bridge to elective LTx, reduction of serum copper
and bilirubin in acute WD
Loock et al. (40), Essen 4 4 Neurological improvement, graft recovery,
reduction of serum bilirubin
Kasakow et al. (41), Jena 1 1 Bridge to re-LTx in an infant (15 month old
infant), reduction of serum bilirubin
Aviles et al. (51), Santa Cruz de Tenerife 3 3 Neurological improvement, disappearance of
pruritus, reduction of serum bilirubin
Seige, Kreymann, et al. (49), Munich 3 3 Neurological improvement (EEG-monitored),
bridge to elective LTx, reduction of bilirubin
Oliviero et al. (52), Mercurio et al. (53), Rome 1 1 Neurological improvement (decrease in resting
motor threshold), reduction of ammonia,
bilirubin, and bile acids
Kapoor et al. (54), London 1 1 Neurological improvement, reduction of PT and
bilirubin
Ullerich et al. (55), Münster 1 1 Neurological improvement, bridge to elective LTx,
reduction of bilirubin
Wilmer et al. (56), Leuven 1 1 Neurological improvement, reduction of bilirubin,
bile acids, and PT
Notohamiprodjo et al. (45), Bad Oyenhausen 7c 7 Neurological improvement, reduction of bilirubin
Huster et al. (44), Leipzig 1d 1 Disappearance of pruritus, reduction of bilirubin
Total 64 12 14 13 103
a 1 liver failure posttrauma; 1 Budd Chiari syndrome; 1 liver failure after hepatectomy in hepatocellular carcinoma and hepatitis B.
b 2 liver failure after hepatectomy.
c 7 liver failure secondary to right ventricular heart failure.
d 1 benign recurrent cholestasis (BRC).
A, acute; AoC, acute on chronic; PGD, primary graft dysfunction; MAP, mean arterial pressure; SVR, systemic vascular resistance;
SjvO2, jugular vein oxygen saturation; ICP, intracranial pressure; INR, international ration; PT, prothrombin time; CTP, Child Turqotte
Pugh score; WD, acute Wilson’s disease.
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the time to recovery and decrease morbidity and
mortality.
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